ArQule to Report First Quarter 2019 Financial Results on May 1, 2019
April 17 2019 - 3:01PM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced it will report
financial results for the first quarter of 2019 before the market
opens on Wednesday, May 1, 2019. The Company will hold a conference
call and webcast on the same day at 9:00 a.m. ET to discuss these
results and provide a general business update.
The live webcast can be accessed in the “Investors and Media”
section of our website, www.arqule.com, under “Events &
Presentations.” You may also listen to the call by dialing (877)
868-1831 within the U.S. or (914) 495-8595 outside the U.S. A
replay will be available two hours after the completion of the call
and can be accessed in the “Investors & Media” section of our
website, www.arqule.com, under “Events and Presentations.”
About ArQuleArQule is a biopharmaceutical company engaged
in the research and development of targeted therapeutics to treat
cancers and rare diseases. ArQule’s mission is to discover, develop
and commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible inhibitor of both wild type and
C481S-mutant BTK, in phase 1 for patients with B-cell malignancies
refractory to other therapeutic options; miransertib (ARQ 092), a
selective inhibitor of the AKT serine/threonine kinase, planned to
initiate registrational trial cohorts in Proteus syndrome and PROS
in 2019, and in phase 1b in combination with the hormonal therapy,
anastrozole, in patients with advanced endometrial cancer; ARQ 751,
a next generation AKT inhibitor, in phase 1 for patients with AKT1
and PI3K mutations; and derazantinib, a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor
receptor (FGFR) family, in a registrational trial for iCCA.
ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190417005763/en/
Corporate Contact:Kathleen FarrenInvestor Relations
&Executive Assistant to the CFOir@arqule.comMedia
Contact:Cait Williamson, Ph.D.LifeSci Public Relations (646)
751-4366cait@lifescipublicrelations.comwww.ArQule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2024 to May 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about ArQule Inc (NASDAQ): 0 recent articles
More Arqule, Inc. News Articles